Navigation Links
ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
Date:6/5/2017

ACEA Biosciences and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaboration to evaluate a personalized ex vivo potency assay using cancer patients’ malignant pleural effusions and ACEA’s xCELLigence Real-Time Cell Analysis (RTCA) instrument to monitor destruction of the cancer cells by the patient’s own genetically modified CAR T cells. ACEA’s xCELLigence RTCA instrument can monitor this cancer cell killing process in real-time without the use of labels so it provides a means of assessing CAR T cell potency under conditions that are of maximal physiological relevance. Dr. Prasad S. Adusumilli, whose laboratory will spearhead this project at MSK, "Said, “the time resolution of this instrument will be an important feature of this ex vivo assay with malignant pleural effusions to understand both the efficacy and the resistance of the patient’s tumor cells to CAR T cell treatment.” Dr. Adusumilli went on to say that, “Because the goal is to determine if this approach can predict a patient’s clinical response to CAR T cells, we will need to determine if the ex vivo assay can capture the complexities of the treatment within the patient.”

Dr. Yama Abassi, ACEA’s Vice President of Global Strategic Business Development and Growth, stated “we are extremely excited to initiate this important project with Dr. Adusumilli and MSK. We are confident that the exquisite sensitivity of the xCELLigence instrument, especially at very low effector to target ratios, will allow us to accurately assess the efficacy of the patients’ CAR T cells against their own tumor cells.” He further stated “since manipulation of the target cells is not required, the RTCA assay is well suited for quantitatively evaluating various combination therapies such as checkpoint inhibitor treatment plus CAR T cells. We believe that real-time, patient-specific assays are a powerful new tool for cancer immunotherapy research that will help inform patient treatment decisions in the future.”

About xCELLigence® RTCA
xCELLigence® Real Time Cell Analysis (RTCA) instruments utilize gold microelectrodes embedded in the bottom of microtiter wells to non-invasively monitor cell number, size, and attachment quality in a label-free manner using the principle of cellular impedance. The high sensitivity of xCELLigence instruments enable them to monitor cell killing at physiologically relevant effector to tumor cell ratios as low as 0.1:1. The real-time kinetic readouts facilitate quantitative potency analyses and provide mechanistic information regarding immune cell regulation and function.    These features, combined with a simple automated workflow and powerful data analysis suite, have led to xCELLigence being widely adapted by immunotherapy researchers across diverse sub-disciplines. These instruments are being used in both academia and industry for basic and applied applications of cancer immunotherapy including, but not limited to: ADCC, BiTEs, CAR Ts, checkpoint inhibitors, NK cells, and cell invasion/migration. To date xCELLigence® has been used in more than 1,250 publications, which can be viewed in a searchable library.

For more information, click here.

For further information please contact:                                                                                    
ACEA Biosciences, Inc.                                                                                                                
Dr. Jeff Xue                                                                                                                                    
Phone: 1-858-724-0928, x3075                                                                                                
email: jxue(at)aceabio(dot)com

Read the full story at http://www.prweb.com/releases/2017/06/prweb14388685.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
2. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
3. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
4. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
5. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
6. TOMA Biosciences Releases the COMPASS Tumor Profiling System
7. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
8. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
9. Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
10. Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
11. DuPont Industrial Biosciences Leader Presents Major Advances in Biomaterials at 2017 Advanced Bioeconomy Leadership Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):